Beam Therapeutics Inc. APIC, Share-based Payment Arrangement, Recognition and Exercise
Beam Therapeutics Inc. (BEAM) reported APIC, Share-based Payment Arrangement, Recognition and Exercise of $4.65 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-11.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions · last filed 2021-05-11
- Beam Therapeutics Inc. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2021-03-31 was $4.65M, a 66.48% increase year-over-year.
- Beam Therapeutics Inc. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2020-09-30 was $3.01M, a 48.45% increase year-over-year.
- Beam Therapeutics Inc. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2020-06-30 was $2.77M, a 33.57% increase year-over-year.
- Beam Therapeutics Inc. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2020-03-31 was $2.79M, a 221.29% increase year-over-year.
- Beam Therapeutics Inc. apic, share-based payment arrangement, recognition and exercise for fiscal 2020 was $15.38M, a 118.84% increase from fiscal 2019.
- Beam Therapeutics Inc. apic, share-based payment arrangement, recognition and exercise for fiscal 2019 was $7.03M.
| Period end | APIC, Share-based Payment Arrangement, Recognition and Exercise 3 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 6 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 9 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 12 month |
|---|---|---|---|---|
| 2021-03-31 | $4.65M 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | $15.38M 10-K · filed 2021-03-15 | |||
| 2020-09-30 | $3.01M 10-Q · filed 2020-11-10 | $5.78M derived: sum of 2 quarters · filed 2020-11-10 | $8.57M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2020-06-30 | $2.77M 10-Q · filed 2020-11-10 | $5.56M derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2020-03-31 | $2.79M 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | $7.03M 10-K · filed 2021-03-15 | |||
| 2019-09-30 | $2.03M 10-Q · filed 2020-11-10 | $4.10M derived: sum of 2 quarters · filed 2020-11-10 | $4.97M derived: sum of 3 quarters · filed 2020-11-10 | |
| 2019-06-30 | $2.07M 10-Q · filed 2020-11-10 | $2.94M derived: sum of 2 quarters · filed 2020-11-10 | ||
| 2019-03-31 | $869.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |